Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation

Transplant International

Volumn 23, Issue 9, 2010, Pages 897-906

  Leone, Francesca ^a   Akl, Ahmed ^a   Giral, Magali ^a   Dantal, Jacques ^a   Blancho, Gilles ^a   Soulillou, Jean Paul ^a   Cantarovich, Diego ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

calcineurin inhibitors; corticosteroids; cytomegalovirus disease; cytomegalovirus prophylaxis; mycophenolate mofetil; polyomavirus; renal transplantation; valacyclovir; valganciclovir

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR; VALGANCICLOVIR;

ADULT; AGED; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HERPES VIRUS INFECTION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

ACYCLOVIR; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT SURVIVAL; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PRODRUGS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VALINE;

EID: 77955250688     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01073.x     Document Type: Article

References (32)

1. Fisher RA. Cytomegalovirus infection and disease in the new era of immunosuppression following solid organ transplantation. Transpl Infect Dis 2009 3 : 195.
2. Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006 82 : S4.
3. Schnitzler MA, Lowell JA, Hardinger KL, Boxerman SB, Bailey TC, Brennan DC. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am J Transplant 2003 3 : 445.
4. Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk for cytomegalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis 2008 47 : 296.
5. Guirado L, Rabella N, Diaz JM, et al. Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir. Nefrologia 2008 28 : 293.
6. Nishida H, Ishida H, Tanaka T, et al. Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy. Transpl Int 2009 22 : 961.
7. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008 10 : 2111.
8. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Metaanalysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005 143 : 870.
9. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000 44 : 2811.
10. Pescovitz MD, Pruett TL, Gonwa T, et al. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 1998 66 : 1104.
11. Singh N, Yu VL, Guyowski T, Marino IR. Changes in the level of CMV antigenemia (pp65) in liver transplant recipients receiving oral ganciclovir as CMV prophylaxis. Transplantation 1999 67 : S98.
12. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000 356 : 645.
13. Reischig T, Jindra P, Mares J, et al. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Transplantation 2005 79 : 317.
14. Pavlopoulou ID, Syriopoulou VP, Chelioti H, et al. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients. Clin Microbiol Infect 2005 11 : 736.
15. Balfour Jr. HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989 320 : 1381.
16. Goral S, Ynares C, Dummer S, Helderman JH. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective? Kidney Int 1996 57 (Suppl. S62.
17. Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996 7 : 325.
18. Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M. International Herpes Management Forum. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes 2008 15 : 4.
19. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006 6 : 262.
20. Poirier-Toulemonde AS, Imbert-Marcille BM, Ferré-Aubineau V, et al. Successful quantification of cytomegalovirus DNA by competitive PCR and detection with capillary electrophoresis. Mol Cell Probes 1997 11 : 11.
21. Poirier-Toulemonde AS, Milpied N, Cantarovich D, Morcet JF, Billaudel S, Imbert-Marcille BM. Clinical relevance of direct quantification of pp65 antigenemia using flow cytometry in solid organ and stem cell transplant recipients. J Clin Microbiol 2000 38 : 3143.
22. Bressollette-Bodin C, Coste-Burel M, Besse B, André-Garnier E, Ferre V, Imbert-Marcille BM. Cellular normalization of viral DNA loads on whole blood improves the clinical management of cytomegalovirus or Epstein Barr virus infections in the setting of pre-emptive therapy. J Med Virol 2009 81 : 90.
23. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systemic review. Am J Transplant 2009 9 : 1254.
24. Rayes N, Seehofer D, Kahl A, et al. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis. Transpl Int 2007 20 : 974.
25. Helanterä I, Lautenschlager I, Koskinen P. Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients. Nephrol Dial Transplant 2009 24 : 316.
26. Manuel O, Venetz JP, Fellay J, et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med Wkly 2007 1 : 669.
27. Giral M, Nguyen JM, Daguin P, et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol 2001 12 : 1758.
28. Helanterä I, Koskinen P, Finne P, et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006 19 : 893.
29. Helanterä I, Loginov R, Koskinen P, Lautenschlager I. Demonstration of HHV-6 antigens in biopsies of kidney transplant recipients with cytomegalovirus infection. Transpl Int 2008 21 : 980.
30. Humar A, Asberg A, Kumar D, et al. VICTOR study group. An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 2009 9 : 374.
31. Taber DJ, Ashcraft E, Baillie GM, et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 2004 6 : 101.
32. Roodnat JI, Mulder PG, Tielens ET, van Riemsdijk IC, van Gelder T, Weimar W. The Cox proportional hazards analysis in words: examples in the renal transplantation field. Transplantation 2004 77 : 483.